|
|
Volumn 42, Issue 2, 2002, Pages 137-143
|
|
Oncology drug development: United States Food and Drug Administration perspective
|
|
Author keywords
Drug approval; Drug development; FDA; Regulatory agency
|
|
Indexed keywords
AMIFOSTINE;
ANASTROZOLE;
ARSENIC TRIOXIDE;
CAPECITABINE;
CELECOXIB;
CLADRIBINE;
CYTARABINE;
DOCETAXEL;
DOXORUBICIN;
EXEMESTANE;
IMATINIB;
IRINOTECAN;
LETROZOLE;
MITOXANTRONE;
PAMIDRONIC ACID;
PENTOSTATIN;
PHOTOFRIN;
RAZOXANE;
RETINOIC ACID;
TAMOXIFEN CITRATE;
TEMOZOLOMIDE;
TOPOTECAN;
TOREMIFENE;
CANCER CHEMOTHERAPY;
CLINICAL RESEARCH;
DRUG APPROVAL;
DRUG MARKETING;
DRUG SAFETY;
DRUG SCREENING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LICENSING;
PRACTICE GUIDELINE;
REVIEW;
RISK BENEFIT ANALYSIS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
DRUG APPROVAL;
HUMANS;
RISK ASSESSMENT;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0036242837
PISSN: 10408428
EISSN: None
Source Type: Journal
DOI: 10.1016/S1040-8428(02)00008-2 Document Type: Review |
|
Times cited : (35)
|
|
References (24)
|
